 |
|
 
|
|
Recent VL Scientific Publications
To learn more about leishmaniasis and the need for new treatments:
1: Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009 Jan;14(1):88-92.
2: Croft SL. Kinetoplastida: new therapeutic strategies. Parasite. 2008 Sep;15(3):522-7.
3: Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr; 21(2):334-59.
4: Janvier F, Morillon M, Olliaro P. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents]. Med Trop (Mars). 2008 Feb; 68(1):89-101.
5: Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008; 2(10):313.
6: Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov; 5(11):873-82.
7: Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21; 356(25):2571-81.
8: Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002 Aug; 2(8):494-501.
1: Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009 Jan;14(1):88-92.
2: Croft SL. Kinetoplastida: new therapeutic strategies. Parasite. 2008 Sep;15(3):522-7.
3: Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008 Apr; 21(2):334-59.
4: Janvier F, Morillon M, Olliaro P. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents]. Med Trop (Mars). 2008 Feb; 68(1):89-101.
5: Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis. 2008; 2(10):313.
6: Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007 Nov; 5(11):873-82.
7: Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21; 356(25):2571-81.
8: Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002 Aug; 2(8):494-501.
Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org